About Us

About our company

UroCure was founded in May 2017 by John Nealon and Dr. David Staskin. Mr. Nealon and Dr. Staskin—together with other medical and industry experts—collaborated to bring an enhanced version of Dr. Staskin’s patented design for midurethral slings back to the marketplace for women suffering from stress urinary incontinence (SUI).

UroCure’s ArcTV® sling incorporates popular features of the AMS vaginal retropubic sling—features which helped position AMS as a global leader in surgical treatment of incontinence by the mid 2000s. With enhancements such as a patented stabilizing suture designed to resist deformation, and a handle-needle assembly designed for the safe and accurate placement of the sling, the ArcTV represents the next generation of surgical solutions for SUI.

A unique approach

Our goal is to improve the quality of life for women suffering from SUI. In pursuit of that mission, UroCure relies on a radical approach: listening. We believe that by listening to women and their doctors about what works best for them, we are paving a new path forward that will have real impact on women’s lives.

As part of this approach, we have intentionally incorporated feedback in every step of our process—from the design of the ArcTV, to its introduction in hospitals and clinics, and finally, post-surgery. Here are three key components of that process that assure transparency and accountability:

We rely on experts.

UroCure is launching its new product in fifty distinguished medical centers and hospitals. Physicians receive UroCure product training prior to first use and commit to tracking their patients’ progress.

We build trust.

In the interest of developing trust among patients and their physicians, UroCure has charted a new course for medical device companies: we have impaneled a Quality and Safety Oversight Committee (QSOC) comprised of leading academic physicians who monitor patient outcomes and guide UroCure’s activities.

We are committed to clinical data collection.

UroCure is partnering with the American Urogynecological Society (AUGS) to gather patient data through its ACQUIRE SUI QI data registry.

Taken altogether, these efforts demonstrate a new business model that emphasizes evidence-based learning and positive outcomes. We have confidence that this focus will not only assure the best patient outcomes but also build long-term acceptance and trust within the healthcare community.